Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 11:35:00 2024-09-06 am EDT 5-day change 1st Jan Change
33.22 EUR -1.72% Intraday chart for Fresenius SE & Co. KGaA -0.45% +18.35%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
FRESENIUS SE : DZ Bank reaffirms its Buy rating ZD
Medical service presents annual statistics on medical errors DP
Shelly Group Co-CEO Exits Role as Managing Director of Shelly DACH GmbH MT
Lack of blood donations: Reserves almost exhausted DP
FRESENIUS SE : Jefferies remains its Buy rating ZD
FRESENIUS SE : Receives a Buy rating from Barclays ZD
FRESENIUS SE : Warburg Research keeps its Buy rating ZD
FRESENIUS : Lots of positives for a strong Q2 Alphavalue
Frankfurt equities close: Cautious optimism ahead of US interest rate decision DP
Global markets live: Airbus, HSBC, Boeing, Microsoft, Starbucks... Our Logo
Transcript : Fresenius SE & Co. KGaA, Q2 2024 Earnings Call, Jul 31, 2024
Barclays reads 'Overweight' for Fresenius SE - Target 36.50 euros DP
FRESENIUS SE : Gets a Neutral rating from Goldman Sachs ZD
FRESENIUS SE : Jefferies remains its Buy rating ZD
FRESENIUS SE : Warburg Research reaffirms its Buy rating ZD
FRESENIUS SE : Deutsche Bank reaffirms its Buy rating ZD
FRESENIUS SE : Barclays remains its Buy rating ZD
FRESENIUS SE : Buy rating from Berenberg ZD
Fresenius earns significantly more in the quarter - beats expectations DP
FRESENIUS SE : JP Morgan remains Neutral ZD
Fresenius beats Q2 expectations on strong unit performance, cost savings RE
Fresenius SE & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Weak US growth forecast weighs on FMC - shares down DP
Dialysis firm FMC cuts outlook for US treatment volumes, shares fall RE
Dialysis specialist FMC's Q2 profit meets expectations RE
Chart Fresenius SE & Co. KGaA
More charts
Logo Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Employees
175,771
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
33.22EUR
Average target price
38.64EUR
Spread / Average Target
+16.32%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Fresenius: Lots of positives for a strong Q2
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW